Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening

INTRODUCTION: Hemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal immunoglobulin for intravenous administration [i.e., intravenous immunoglobulin (IVIG)]. Anti-A/B isoagglutinins (also referred to as isohemagglutinins) originating from d...

Descripción completa

Detalles Bibliográficos
Autores principales: Siani, Brigitte, Willimann, Katharina, Wymann, Sandra, Marques, Adriano A., Widmer, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254866/
https://www.ncbi.nlm.nih.gov/pubmed/24841428
http://dx.doi.org/10.1007/s13554-014-0016-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254866/
https://www.ncbi.nlm.nih.gov/pubmed/24841428
http://dx.doi.org/10.1007/s13554-014-0016-2

Ejemplares similares